Regeneron Pharmaceuticals, Inc. Earnings

Regeneron Pharmaceuticals, Inc.’s revenue fell -3.7% since last year same period to $3028.7Mn in the Q1 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -20.07% fall in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit jumped 12.01% since last year same period to $808.7Mn in the Q1 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -11.88% fall in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin jumped 16.31% since last year same period to 26.7% in the Q1 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 10.25% jump in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 15.39.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 8.48 - a -25.51% fall from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 8.48.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) fell -13.93% since last year same period to 8.22 in the Q1 2025. This indicates that the Regeneron Pharmaceuticals, Inc. has generated -13.93% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regeneron Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regeneron Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.16.

Regeneron Pharmaceuticals, Inc. declared 0.88 dividend per share during the earnings announcement for Q1 2025.